Reports from Department of Hematology-Oncology Advance Knowledge in Breast Cancer (Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials)

MLA

“Reports from Department of Hematology-Oncology Advance Knowledge in Breast Cancer (Bevacizumab in the Neoadjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials).” Women’s Health Weekly, Mar. 2019, p. 416. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.579945298&authtype=sso&custid=ns315887.

APA

Reports from Department of Hematology-Oncology Advance Knowledge in Breast Cancer (Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials). (2019, March 28). Women’s Health Weekly, 416.

Chicago

Women’s Health Weekly. 2019. “Reports from Department of Hematology-Oncology Advance Knowledge in Breast Cancer (Bevacizumab in the Neoadjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials),” March 28. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.579945298&authtype=sso&custid=ns315887.